RBx
On the Nox Insights page on the company website, Professor Kelly made a forward looking statement in July last year, that we would be hearing a lot more about STING.
Although not necessarily in the current context, but he seems to have made a astute prediction nonetheless.
A big tick for Veyonda with respect to STING in this set of circumstances, would by reason give it further credibility in the oncology arena.
Interesting times for all stakeholders.
FDA Emergency Use Authorization (EUA), page-5
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
